Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olpadronate intravenous treatment for chronic non-specific low back pain
NL-OMON46893Phase 2Active, not recruiting
- Sponsor
- Gador S.A.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olpadronate in Low back pain (LBP), degenerative disc disease (DDD) and lumbar spondylosis (3 arms), sponsored by Gador S.A. Primary endpoint: Primary: Change from baseline in pain score at Week 24. Started Jun 2016; status: active, not recruiting.
02
Drugs
olpadronate
03
Conditions
Low back pain (LBP)degenerative disc disease (DDD)lumbar spondylosis
Beyond the preview
Go deeper on NL-OMON46893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46893.